Curated News
By: NewsRamp Editorial Staff
June 30, 2026

HeartBeam Completes Heart Attack Detection Study Ahead of Schedule

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • HeartBeam completed ALIGN-ACS enrollment early, potentially accelerating FDA approval for heart attack detection and gaining market edge.
  • The ALIGN-ACS pilot study enrolled 120 chest pain patients, comparing standard 12-lead ECG with HeartBeam's 3D ECG technology.
  • HeartBeam's 3D ECG technology could enable earlier heart attack detection, improving patient outcomes and reducing cardiac emergencies.
  • HeartBeam's cable-free 3D ECG synthesizes signals into a 12-lead ECG, potentially allowing heart monitoring anywhere.

Impact - Why it Matters

This news matters because heart attacks are a leading cause of death worldwide, and early detection is critical for survival. The HeartBeam System, with its portable 3D ECG technology, has the potential to revolutionize cardiac care by enabling patients to receive timely diagnosis outside of medical facilities. If successful, this could reduce delays in treatment, improve outcomes, and lower healthcare costs. The accelerated enrollment signals strong interest and potential for faster regulatory approval, bringing this life-saving technology closer to patients.

Summary

HeartBeam (NASDAQ: BEAT) has announced the completion of patient enrollment ahead of schedule in its ALIGN-ACS pilot study, which evaluates the HeartBeam System for heart attack detection. The study enrolled 120 patients presenting with chest pain at two clinical sites in Belgrade, Serbia. Participants were evaluated using both a standard 12-lead ECG and the company’s innovative 3D ECG technology. Data analysis is currently underway, and HeartBeam plans to present the results at a major cardiology conference later this year. The company anticipates that the study results will support discussions with the FDA on the design of a planned U.S. pivotal trial and a future submission to expand the HeartBeam System’s indication beyond arrhythmia assessment to include heart attack detection.

HeartBeam is also evaluating whether completing enrollment ahead of its previously anticipated third-quarter 2026 timeline could support a more accelerated regulatory pathway. The HeartBeam System is the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, redefining the future of cardiac health management.

HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. The full press release is available at https://ibn.fm/GEYtp. For more information about HeartBeam and its technology, visit the company’s newsroom at https://ibn.fm/BEAT.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, HeartBeam Completes Heart Attack Detection Study Ahead of Schedule

blockchain registration record for this content.